Acute leukemia in children

Current Opinion in Hematology

Volumn 3, Issue 4, 1996, Pages 249-258

  Pui, Ching Hon ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; DISEASE CLASSIFICATION; GENE REARRANGEMENT; HUMAN; LEUKEMIA CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

EID: 0030035826     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603040-00002     Document Type: Review

References (104)

1. Miller RW, Young JL, Novakovic B: Childhood cancer. Cancer 1994, 75:395-405.
2. Pui C-H, Crist WM: Treatment of childhood leukemias. Curr Opin Oncol 1995, 7:36-44.
3. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK, eds: SEER Cancer Statistics Review 1973-1991: Tables and Graphs. Bethesda: National Cancer Institute; 1994 (NIH publication no. 94-2789).
4. Pui C-H: Childhood leukemias [reply to a letter]. N Engl J Med 1995, 333:1286-1287.
5. Shu X-O, Ross JA, Pendergrass TW, Reaman GH, Lampkin B, Robison LL: Parental alcohol consumption, cigarette smoking, and risk of Infant leukemia: a Childrens Cancer Group Study. J Natl Cancer Inst 1996, 88:24-31.
6. Douer D, Preston-Martin S, Chang E, Nichols PW, Watkins KJ, Levine AM: • High frequency of acute promyelocytic leukemia among Latinos with acute myelold leukemia. Blood 1996, 87:308-313. Among patients with AML, acute promyelocytic leukemia was noted in 24.3% to 37.5% of those of Latin American heritage but in only 6.5% to 8.3% of those from other ethnic groups.
7. Pui C-H: Acute lymphoblastic leukemia. Hong Kong J Paediatr 1996, in press.
8. Pui C-H: Childhood leukemias. N Engl J Med 1995, 332:1618-1630. • A concise review of biology and treatment of childhood leukemias with 159 references.
9. European Group for the Immunological Characterization of Leukemias (EGIL), Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB: Proposals for the immunological classification of acute leukemias. Leukemia 1995, 9:1783-1786.
10. Pui C-H, Campana D, Crist WM: Toward a clinically useful classification of the acute leukemias. Leukemia 1995, 9:2154-2157.
11. Campana D, Pui C-H: Detection of minimal residual disease in acute • leukemia: methodologic advances and clinical significance. Blood 1995, 85:1416-1434. A comprehensive review of the advances and clinical significance of various methods in the detection of minimal residual leukemia
12. Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Löffler H, Riehm H, Schellong G, Ludwig W-D: Clinical significance of surface antigen expression in children with acute myelold leukemia: results of study AML-BFM-87. Blood 1995, 86:3097-3108.
13. Smith FO, Rauch C, Williams DE, March CJ, Arthur D, Hilden J, Lampkin BC, Buckley JD, Buckley CV, Woods WG, Dinndorf PA, Sorensen P, Kersey J, Hammond D, Bernstein ID: The human homologue of rat NG 2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myelold leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 1996, 87:1123-1133.
14. Behm FG, Smith FO, Raimondi SC, Pui C-H, Bernstein ID: Human homologue of the rat chondroitin sulfate proteoglycan, NG 2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 1996, 87:1134-1139.
15. Porwit-MacDonald A, Janossy G, Ivory K, Swirsky D, Peters R, Wheatley K, Walker H, Turker A, Goldstone AH, Burnett A: Leukemia-associated changes identified by quantitative flow cytometry IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 1996, 87:1162-1169.
16. van Wering ER, Beishuizen A, Roeffen ETJM, van der Linden-Schrever BEM, Verhoeven M-AJ, Hählen K, Hooijkaas H, van Dongen JJM: Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. Leukemia 1995, 9:1523-1533.
17. Macedo A, San Miguel JF, Vidnales MB, López-Berges MC, Garcia-Marcos MA, Gonzalez M, Landolfi C, Orfāo A: Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. J Clin Pathol 1996, 49:15-18.
18. Pui C-H, Campana D: Detection of Minimal Residual Disease in Acute Leukemia. Education Program. Singapore: The International Society of Haematology Congress 1996, in press.
19. Martinez-Climent JA, Lane NJ, Rubin CM, Morgan E, Hohnstone HS, Mick R, Murphy SB, Vardiman JW, Larson RA, Le Beau MM, Rowley JD: Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia 1995, 9:95-101.
20. Hwang L-Y, Baer RJ: The role of chromosome translocations in T-cell acute leukemia. Curr Opin Immunol 1995, 7:659-664.
21. Slater R, Smit E, Kroes W, Jotterand Bellomo M, Mühlematter D, Harbott J, Behrendt H, Hählen K, Veerman AJP, Hagemeijer A: A non-random chromosome abnormality found in precursor-B lineage acute lymphoblastic leukaemia: dic(9;20)(p1?3;q11). Leukemia 1995, 9:1613-1619.
22. Raimondi SC, Frestedt JL, Pui C-H, Downing JR, Head DR, Kersey JH, Behm FG: Acute lymphoblastic leukemias with deletion of 11q23 or a novel Inversion (11)(p13q23) lack MLL gene rearrangements and have favorable clinical features. Blood 1995, 86:1881-1886.
23. Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, Rivera •• GK, Kersey JH, Pui C-H: Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996, 87:2870-2877. In a stratified analysis adjusted for age and treatment protocol, MLL gene rearrangement was correlated with an inferior treatment outcome among patients with 11q23 rearrangements. The 4-year event-free survival (± SE) was 10% ± 6.5% for patients with the MLL rearrangement and 64% ± 19% for those with other 11q23 abnormalities (not involving the MLL gene), underscoring the importance of molecular analysis in risk assessment of children with ALL.
24. Hilden JM, Frestedt JL, Moore RO, Heerema NA, Arthur DC, Reaman GH, Kersey JH: Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4;11)(q21;q23). Blood 1995, 86:3876-3882.
25. Romana SP, Mauchauffé M, Le Coníat M, Chumakov I, Le Paslier D, Berger R, Bernard OA: The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 1995, 85:3662-3670.
26. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland DG: Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 1995, 92:4917-4921.
27. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, •• Chan GC-F, Pui C-H, Grosveld G, Downing JR: TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995, 9:1985-1989. The authors demonstrate a TEL/AML chimeric transcript encoded by a cryptic t(12;21) in 22% of children with newly diagnosed ALL, making it the most frequent genetic lesion in childhood leukemia. This genetic abnormality appears to define a distinct subgroup of ALL cases with a B-lineage phenotype, between 1 and 10 years of age, having a nonhyperdiploid karyotype, and favorable responses to therapy.
28. Romana SP, Poirel H, Leconiat M, Flexor M-A, Mauchauffé M, Jonveaux P, •• Macintyre EA, Berger R, Bernard OA: High frequency of t(12;21) in childhood B-Ilneage acute lymphoblastic leukemia. Blood 1995, 86:4263-4269. TEL/AML fusion was found in eight (22%) of 36 children with B-lineage ALL but in none of 24 adult cases.
29. Raynaud S, Cave H, Baens M, Bastard C, Cacheux V, Grosgeorge J, Guidal-Giroux C, Guo C, Vilmer E, Marynen P, Grandchamp B: The t12;21 translocation involving TEL and deletion of other TEL alleles: two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996, 87:3891-2899.
30. Liang D-C, Chou T-B, Chen J-S, Shurtleff SA, Rubnitz JE, Downing JR, Pui C-H, Shih L-Y: High incidence of TEL/AML1 fusion resulting from a cryptic t(12;21) in childhood B-lineage acute lymphoblastic leukemia in Taiwan. Leukemia 1996, in press.
31. Stegmaier K, Pendse S, Barker GF, Bray-Ward P, Ward DC, Montgomery KT, Krauter KS, Reynolds C, Sklar J, Donnelly M, Bohlander SK, Rowley JD, Sallan SE, Gilliland DG, Golub TR: Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood. Blood 1995, 86:38-44.
32. Bash RO, Hall S, Timmons CF, Crist WM, Amylon M, Smith RG, Baer R: • Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A Pediatric Oncology Group Study. Blood 1995, 86:666-676. Ectopic expression of TAL1 was found in two thirds of T-cell ALL cases, including many that did not have obvious alterations of the gene. The finding suggests that the TAL1 gene plays a prominent role in the development of T-cell ALL.
33. Kawamura M, Kikuchi A, Kobayashi S, Hanada R, Yamamoto K, Horibe K, Shikano T, Ueda K, Hayashi K, Sekiya T, Hayashi Y: Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia. Blood 1995, 85:2546-2552.
34. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, Brodsky I, Haines DS: High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood 1996, 87:1155-1161.
35. Quesnel B, Preudhomme C, Philippe N, Vanrumbeke M, Dervite I, Lai JL, • Bauters F, Wattel E, Fenaux P: p16 Gene homozygous deletions in acute lymphoblastic leukemia. Blood 1995, 85:657-663. Homozygous deletion of the p16 gene was found in nine of 63 ALL cases (14%) but not in cases with AML, myelodysplastic syndrome, chronic lymphocytic leukemia, or multiple myeloma.
36. INK4b/MTS2 in pediatric acute lymphoblastic leukemia. Blood 1995, 85:2321-2330. In this study, a higher frequency of p16 deletion was found in T-cell ALL than in B-lineage ALL. A p16 deletion appeared to correlate with an inferior treatment outcome.
37. Takeuchi S, Bartram CR, Seriu T, Miller CW, Tobler A, Janssen JWG, Reiter A, Ludwig W-D, Zimmermann M, Schwaller J, Lee E, Miyoshi I, Koeffler HP: Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood 1995, 86:755-760.
38. Ohnishi H, Kawamura M, Ida K, Sheng XM, Hanada R, Nobori T, Yamamori S, Hayashi Y: Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood 1995, 86:1269-1275.
39. Steenbergen EJ, Verhagen OJHM, van Leeuwen EF, van den Berg H, von dem Bome AEGK, van der Schoot CE: Frequent ongoing T-cell rearrangements in childhood B-precursor acute lymphoblastic leukemia: implications for monitoring minimal residual disease. Blood 1995, 86:692-702.
40. Marshall GM, Kwan E, Haber M, Brisco MJ, Sykes PJ, Morley AA, Toogood I, Waters K, Tauro G, Ekert H, Norris MD: Characterization of clonal immunoglobulin heavy chain and T cell receptor γ gene rearrangements during progression of childhood acute lymphoblastic leukemia. Leukemia 1995, 9:1847-1850.
41. Steenbergen EJ, Verhagen OJHM, van Leeuwen EF, van den Berg H, Behrendt H, Slater RM, von dem Borne AEGKr, van der School CE: Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia 1995, 9:1726-1734.
42. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan S, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R: Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1995, 14:18-24.
43. Uckun FM, Sather H, Reaman G, Shuster J, Land V, Trigg M, Gunther R, • Chelstrom L, Bleyer A, Gaynon P, Crist W: Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood 1995, 85:873-878. Among 42 children with newly diagnosed high-risk B-lineage ALL, the 23 patients whose leukemic cells caused overt leukemia in mice with severe combined immunodeficiency had a 5-year estimated event-free survival of 29.5%, significantly lower than the 94.7% in the other 19 patients whose leukemic cells failed to grow.
44. Kumagai M-A, Manabe A, Pui C-H, Behm FG, Raimondi SC, Hancock ML, Mahmoud H, Crist WM, Campana D: Stroma-supported culture of childhood B-lineage lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 1996, 97:755-760. Among children with newly diagnosed B-lineage ALL who were studied for leukemic cell growth in stromal cell culture system, the probability of 4-year event-free survival (±SE) was 50% ±9% in the 35 patients with higher cell recovery and 94% ±6% in the remaining 35 (P=0.0003).
45. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Chappell R, Hammond D, Bleyer WA: Cytoreduction and prognosis in acute lymphoblastic leukemia: the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol 1996, 14:389-398.
46. Aricò M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E, Zanesco L, Rondelli R, Pession A, Masera G, for the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP): Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer 1995, 75:1684-1693.
47. Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, • Crist WM, Pui C-H: Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995, 86:1292-1295. In this series of 297 children treated with effective, risk-based therapy for ALL, the persistence of circulating blasts after 1 week of conventional multiagent remission induction chemotherapy was an important early predictor of subsequent treatment failure.
48. Coustan-Smith E, Kitanaka A, Pui C-H, , McNinch L, Evans WE, Raimondi SC, Behm FG, Aricó M, Campana D: Clinical relevance of BCL-2 over-expression in childhood acute lymphoblastic leukemia. Blood 1996, 87:1140-1146.
49. Chessells JM, Richards SM, Bailey CC, Lilleyman JS, Eden OB: Gender and treatment outcome in childhood lymphoblastic leukemia: report from the MRC UKALL trials. Br J Haematol 1995, 89:364-372.
50. Pui C-H, Boyett JM, Hancock ML, Pratt CB, Meyer WH, Crist WM: • Outcome of treatment for childhood cancer in black as compared with white children. The St. Jude Children's Research Hospital experience, 1962 through 1992. JAMA 1995, 273:633-637. The authors suggest that with equal access to effective protocol-based therapy, black children with cancer fare as well as white children.
51. Broniscer A, Ribeiro RC, Rivera GK, Raimondi S, Hancock M, Sandlund JT, Crist WM, Pui C-H: Curability of Ph+ childhood acute lymphoblastic leukemia with intensive chemotherapy: prognostic importance of the initial white blood cell count [abstract]. Blood 1995, 6(suppl 1):176a.
52. Cimino G, Rapanotti MC, Rivolta A, Lo Coco F, D'Arcangelo E, Rondelli R, Basso G, Barisone E, Rosanda C, Santostasi T, Canaani E, Masera G, Mandelli F, Biondi A: Prognostic relevance of ALL-t gene rearrangement in infant acute leukemias. Leukemia 1995, 9:391-395.
53. Behrendt H, Charrin C, Gibbons B, Harrison CJ, Hawkins JM, Heerema NA, Horschler-Bötel BH, Huret J-L, Lai JL, Lampert F, Nelken B, Perot C, Ritterbach J, Schlegelberger B, Secker-Walker L, Slater R, Slovak ML, Tanzer J, Van den Akker J: Dicentric (9;12) in acute lymphocystic leukemia and other hematological malignancies: report from a dic(9;12) study group. Leukemia 1995, 9:102-106.
54. Martinez-Climent JA, Espinosa R III, Thirman MJ, Le Beau MM, Rowley JD: Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias. J Pediatr Hematol Oncol 1995, 17:277-283.
55. Ravindrananth Y, Chang M, Camitta B, Steuber CP, Carroll A, Gresik MV, Raimondi S, Weinstein H for the POG: Prognostic factors in childhood acute myeloid leukemia (AML): experience of pediatric oncology group (POG) 8821 AML study [abstract]. Blood 1995, 86(suppl 1):599a.
56. Sievers EL, Smith FO, Woods WG, Lee JW, Bleyer WA, Willman CL, Bernstein ID: Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. Leukemia 1995, 9:2042-2048.
57. Chessells JM, Bailey C, Richards SM, for the Medical Research Council •• Working Party on Childhood Leukemia: Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK medical research council trial UKALL X. Lancer 1995, 345:143-148. This randomized study demonstrates the benefits of early intensification therapy, even in children with lower-risk ALL.
58. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan SE, Sanders SP, • Orav EJ, Gelber RD, Colan SD: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995, 332:1738-1743. Female sex and a higher rate of administration were risk factors of doxorubicin-induced cardiomyopathy, the prevalance and severity of which increased with longer follow-up.
59. Pui C-H, Relling MV, Rivera GK, Hancock ML, Raimondi SC, Heslop HE, Santana VM, Ribeiro RC, Sandlund JT, Mahmoud HH, Evans WE, Crist WM, Krance RA: Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia 1995, 9:1990-1996. The risk of epipodophyllotoxin-induced AML was related to the treatment schedule, concomitant use of other agents and, to a lass extent, the cumulative dose.
60. Pui C-H, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, Krance RA, Mahmoud HH, Ribeiro RC, Sandlund JT, Head DR, Crist WM, Rivera GK: L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995, 9:1680-1684.
61. Kaspers GJL, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJP: Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995, 85:751-756.
62. Schmiegelow K, Schreder H, Gustafsson G, Kristinsson J, Glomstein A, • Salmi T, Wranne L, for the Nordic Society for Pediatric Hematology and Oncology: Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. J Clin Oncol 1995, 13:345-351. This study illustrates large interpatient variabilities in the accumulation of active metabolites of methotrexate and mercaptopurine in children treated with antimetabolite-based therapy for ALL, with higher levels correlated with a favorable outcome.
63. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H, • Crist WM, Pui C-H, Evans WE: Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 1994, 94:1996-2001. The first study showing that high-dose methotrexate achieves higher drug polyglutamate concentrations in leukemic cells, establishing a biochemical rationale for use of high doses of this agent.
64. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui C-H, Evans WE: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo: a rationale for high-dose methotrexate. J Clin Invest 1996, 97:73-80.
65. Mahoney DH Jr, Camitta BM, Leventhal BG, Shuster JJ, Civin CJ, Ganick DJ, Lauer SJ, Steuber CP, Kamen BA: Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group Pilot Study. Cancer 1995, 75:2623-2631.
66. Matherly LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, Gimotty P, Buck S, Wright JE, Rosowsky A: Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia. Blood 1995, 2:500-509.
67. Göker E, Waltham M, Kheradpour A, Trippett T, Mazumdar M, Elisseyeff Y, Schnieders B, Steinherz P, Tan C, Berman E, Bertino JR: Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 1995, 86:677-684.
68. Waber DP, Tarbell NJ, Fairclough D, Atmore K, Castro R, Isquith P, Lussier F, Romero I, Carpenter PJ, Schiller M, Sallan SE: Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice. J Clin Oncol 1995, 13:2490-2496.
69. Christie D, Leiper AD, Chessells JM, Vargha-Khadem F: Intellectual performance after presymptomatic cranial radiotherapy for leukaemia: effects of age and sex. Arch Dis Child 1995, 73:136-140.
70. Didcock E, Davies HA, Didi M, Ogilvy Stuart AL, Wales JKH, Shalet SM: Pubertal growth in young adult survivors of childhood leukemia. J Clin Oncol 1995, 13:2503-2507.
71. 2 over 24 hours for four courses) alone, on the other hand, was inadequate for subclinical central nervous system therapy, even in low-risk cases.
72. Hasle H, Helgestad J, Christensen JK, Jacobsen BB, Kamper J: Prolonged intrathecal chemotherapy replacing cranial irradiation in high-risk acute lymphatic leukaemia: long-term follow up with cerebral computed tomography scans and endocrinological studies. Eur J Pediatr 1995, 154:24-29.
73. van den Berg H, Vet R, den Ouden E, Behrendt H: Significance of lymphoblasts in cerebrospinal fluid in newly diagnosed pediatric acute lymphoblastic malignancies with bone marrow involvement: possible benefit of dexamethasone. Med Pediatr Oncol 1995, 25:22-27.
74. Veerman AJP, Hählen K, Kamps WA, Van Leeuwen V, DeVaan GAM, Solbu G, Suciu S, Van Wering ER, Van der Does-Van den Berg A: High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996, 14:911-918.
75. Relling MV, Mahmoud HH, Pui C-H, Sandlund JT, Rivera GK, Ribeiro RC, Crist WM, Evans WE: Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol 1995, 14:399-404.
76. Uderzo C, Valsecchi MG, Bacigalupo A, Meloni G, Messina C, Polchi P, di Girolamo G, Dini G, Miniero R, Locatelli F, Collelea R, Tamaro P, Lo Curto M, Di Tullio MT, Masera G: Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten year experience of the italian bone marrow transplantation group and the Italian Pediatric Hematology Oncology Association. J Clin Oncol 1995, 13:352-358.
77. Borgmann A, Schmid H, Hartmann R, Baumgarten E, Hermann K, • Klingebiel T, Ebell W, Zintl F, Gadner H, Henze G, for the Berlin-Frankfurt-Münster Study Group: Autologous bone-marrow transplants compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission: a matched-pair analysis. Lancet 1995, 346:873-876. In this multicenter trial, matched-pair analysis revealed similar treatment outcomes between 52 patients who received autologous bone marrow transplants and 52 matched controls who received chemotherapy alone as postinduction treatment during second remission.
78. Moussalem M, Esperou Bourdeau H, Devergie A, Brauchel A, Ribaud P, Socie G, Parquet N, Traineau R, Hirsch I, Schaison G, Gluckman E: Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission: factors predictive of survival, relapse and graft-versus-host disease. Bone Marrow Transplant 1995, 15:943-947.
79. Uderzo C, Rondelli R, Dini G, Dallorso S, Messina C, Miniero R, Locatelli F, De Manzini A, Pession A, Balduzzi A, Locasciulli A, Masera G: High-dose vincristine, fractionated total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7-year Italian Multicentre Study. Br J Haematol 1995, 89:790-797.
80. Ribeiro RC, Rivera GK, Hudson M, Mulhern RK, Hancock ML, Kun L, Mahmoud H, Sandlund JT, Crist WM, Pui C-H: Intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. J Clin Oncol 1995, 13:333-338.
81. Kumar P, Kun LE, Hustu HO, Mulhern RK, Hancock ML, Coffey D, Rivera GK: Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys 1995, 31:477-483.
82. Amadori S, Testi AM, Moleti ML, Giona F, Rolla M, Pession A, Rondelli R, De Rosa M, Di Tullo MT, Mandelli F: Intensified early therapy for child-hood leukemia (AML): pilot studies of the AIEOP Cooperative Group [abstract]. Ann Hematol 1995, 70(suppl II):107a.
83. Creutzig U, Ritter J, Zimmermann M, Schellong G: Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood acute myelogenous leukemia study BFM-87. J Clin Oncol 1993, 2:279-286.
84. Woods WG, Kobrinsky N, Buckley J, Sanders J, Neudorf S, Gold S, Barnard D, DeSwarte J, Dusenbery K, Kalousek D, Arthur D, Lange BJ, for the Childrens Cancer Group (CCG): Timed sequential induction therapy improves post-remission outcome in acute myeloid leukemia (AML) [abstract]. Ann Hematol 1995, 70(suppl II):107a.
85. Béhar C, Suciu S, Benoit Y, Robert A, Vilmer E, Boutard P, Bertrand Y, Lutz P, Ferster A, Tokaji E, Manel A-M, Solbu G, Otten J: Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872. Med Padiatr Oncol 1996, 26:173-179.
86. Michel G, Leverger G, Leblanc T, Nelken B, Baruchel A, Landman-Parker J, Thuret I, Bergeron C, Bordigoni P, Esperou-Bourdeau H, Perel Y, Vannier JP, Schaison G: Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant 1996, 17:191-196.
87. Ravindranath Y, Krischer J, Yeager AM, Steuber CP, Graham-Pole J, Camitta B, Weinstein HJ for the POG: A randomized comparison of purged autologous bone marrow transplantation (ABMT) and consolidation chemotherapy (CC) for acute myelogenous leukemia in children [abstract]. Ann Hematol 1995, 70(suppl II):107a.
88. R gene marking [abstract]. Blood 1995, 86(suppl 1):433a.
89. Magrath I: Bone marrow transplantation for leukaemia: a lame stalking horse for use of high-technology medical care. Lancet 1995, 345:601-602.
90. Gale RP, Goldman JM, Horowitz MM, Silberman G, Crosse MG, Peterson EA: Bone-marrow transplantation for leukaemia [letter]. Lancet 1995, 345:1235.
91. Shaw PJ: Bone-marrow transplantation for leukaemia [letter]. Lancet 1995, 345:1236.
92. Pinkel D: Bone-marrow transplantation [letter]. Lancet 1995, 346:60.
93. Creutzig U, Ritter J, Zimmermann M, Bender-Götze C, Schellong G: Bone-marrow transplantation [letter]. Lancet 1995, 346:60.
94. Casper J, Camitta B, Truitt R, Baxter-Lowe LA, Bunin N, Lawton C, Murray K, Hunter J, Pietryga D, Garbrecht F, Taylor CK, Drobyski W, Horowitz M, Flomenberg N, Ash R: Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood 1995, 85:2354-2363.
95. Davies SM, Shu XO, Blazar BR, Filipovich AH, Kersey JH, Krivit W, McCullough J, Miller WJ, Ramsay NKC, Segall M, Wagner JE, Weisdorf DJ, McGlave PB: Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility on outcome. Blood 1995, 86:1636-1642.
96. Balduzzi A, Gooley T, Anasetti C, Sanders JE, Martin PJ, Petersdorf EW, Appelbaum FR, Buckner CD, Matthews D, Storb R, Sullivan KM, Hansen JA: Unrelated donor marrow transplantation in children. Blood 1995, 86:3247-3256.
97. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995, 86:3508-3603.
98. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clone from the donor. NEngl J Med 1995, 333:1038-1044.
99. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE: Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995, 89:98-103.
100. Schultz KR, Green GJ, Wensley D, Sargent MA, Magee JF, Spinelli JJ, Pritchard S, Davis JH, Rogers PCJ, Chan KW, Phillips GL: Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 1994, 84:3212-3220.
101. Bearman SI: The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995, 85:3005-3020.
102. Thuret I, Michel G, Carla H, Chambost H, Biaise D, Demeocq F, Maraninchi D: Long-term side effects in children receiving allogeneic bone marrow transplantation in first complete remission of acute leukaemia. Bone Marrow Transplant 1995, 15:337-341.
103. Huma Z, Boulad F, Black P, Heller G, Sklar C: Growth in children after bone marrow transplantation for acute leukemia. Blood 1995, 86:819-824.
104. Giorgiani G, Bozzola M, Locatelli F, Picco P, Zecca M, Cisternino M, Dallorso S, Bonetti F, Dini G, Borrone C, Regazzi MB, De Stelano P, Seven F: Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood 1995, 86:825-831.